CRISPR Knockout of the HuR Gene Causes a Xenograft Lethal Phenotype.
Publication/Presentation Date
6-1-2017
Abstract
Pancreatic ductal adenocarcinoma (PDA) is the third leading cause of cancer-related deaths in the United States, whereas colorectal cancer is the third most common cancer. The RNA-binding protein HuR (ELAVL1) supports a pro-oncogenic network in gastrointestinal (GI) cancer cells through enhanced HuR expression. Using a publically available database, HuR expression levels were determined to be increased in primary PDA and colorectal cancer tumor cohorts as compared with normal pancreas and colon tissues, respectively. CRISPR/Cas9 technology was successfully used to delete the HuR gene in both PDA (MIA PaCa-2 and Hs 766T) and colorectal cancer (HCT116) cell lines. HuR deficiency has a mild phenotype,
Volume
15
Issue
6
First Page
696
Last Page
707
ISSN
1557-3125
Published In/Presented At
Lal, S., Cheung, E. C., Zarei, M., Preet, R., Chand, S. N., Mambelli-Lisboa, N. C., Romeo, C., Stout, M. C., Londin, E., Goetz, A., Lowder, C. Y., Nevler, A., Yeo, C. J., Campbell, P. M., Winter, J. M., Dixon, D. A., & Brody, J. R. (2017). CRISPR Knockout of the HuR Gene Causes a Xenograft Lethal Phenotype. Molecular cancer research : MCR, 15(6), 696–707. https://doi.org/10.1158/1541-7786.MCR-16-0361
Disciplines
Business Administration, Management, and Operations | Health and Medical Administration | Management Sciences and Quantitative Methods
PubMedID
28242812
Department(s)
Administration and Leadership
Document Type
Article